#WIMMReads 🧪 From the Peter McHugh Group: a new study reveals how mutations in the proteins CDIN1 and Codanin 1 disrupt an RNA cutting enzyme complex, providing new insight into the rare blood disorder Congenital Dyserythropoietic Anaemia type I. #Haematology #RareDisease #AcademicSky

July is # SarcomaAwarenessMonth: www.macmillan.org.uk/cancer-aware... Sarcomas are fairly rare cancers generally but common in people with Li Fraumeni Syndrome (LFS). To learn about the MILI trial and LFS, visit mili.octru.ox.ac.uk #TP53 #LFS @oncology.ox.ac.uk @oxfordcancer.bsky.social

Research from the Ramadan Lab uncovers a previously unrecognised mechanism of resistance to PARP inhibition💡 The team showed that PARPi-induced trapped PARP1 is cleared via TEX264-mediated nucleophagy. Disrupting this pathway increases PARP1 trapping, re-sensitizing PARPi-resistant cells:

Nucleophagy removes cytotoxic trapped PARP1 - Nature Cell Biology

Hoslett et al. show that trapped PARP1 is cleared from the nucleus by nucleophagy involving the autophagy receptor TEX264 and p97. Inactivation of nucleophagy resensitizes acquired resistance of BRCA1...

nature.com

Last week, Mr Keaton Jones attended a Pancreatic Cancer UK parliamentary reception that brought together 50 MPs, government representatives, researchers, patients, and supporters to discuss how the UK can accelerate progress in pancreatic cancer treatment. ➡️ www.oncology.ox.ac.uk/news/keaton-...

Mr Keaton Jones attends Pancreatic Cancer UK parliamentary reception

Last week, Mr Keaton Jones attended a Pancreatic Cancer UK parliamentary reception at the House of Commons which brought together 50 MPs, government representatives, researchers, patients, and suppor...

oncology.ox.ac.uk

NEWS: New biomarker brings personalised Polθ inhibitor-radiotherapy treatment closer to the clinic Read about the @oncology.ox.ac.uk and Artios Pharma study.

New biomarker brings personalised Polθ inhibitor-radiotherapy treatment closer to the clinic

A new study led by Professor Geoff Higgins at the Department of Oncology, in collaboration with Artios Pharma, has uncovered a genetic vulnerability that could help identify patients most likely to benefit from a promising radiotherapy combination treatment. Published today in Science Advances, the research identifies loss of SHLD2 as a predictive biomarker for treatment with DNA polymerase theta (Polθ) inhibitors, an emerging class of DNA repair-targeted drugs.

medsci.ox.ac.uk

📣 First trial of vaccine to prevent Lynch syndrome-associated cancers approved to start in Oxford. Fantastic news from @ox.ac.uk & Moderna that Phase 1 of the INTERCEPT-Lynch trial has received MHRA authorisation & is expected to begin recruitment this summer. tinyurl.com/intercept-ly...

7th June was #NationalCancerSurvivorsDay, a day to raise awareness about cancer and to honour those who are or have been affected by the disease. www.ourcancerstories.com/cancer-news/... Info on the MILI trial and LFS: mili.octru.ox.ac.uk #TP53 #LFS @oncology.ox.ac.uk @oxfordcancer.bsky.social

🆕New research from the @hammond-lab.bsky.social The team demonstrate that TPM3 is a hypoxia-inducible gene in TNBC that supports F-actin organisation. TPM3 loss impaired motility & invasion in hypoxic TNBC cells, while not affecting viability, underscoring its potential as a therapeutic target.

HIF-1–regulated TPM3 links hypoxia to motility and invasion beyond the hypoxic fraction in triple-negative breast cancer - npj Breast Cancer

npj Breast Cancer - HIF-1–regulated TPM3 links hypoxia to motility and invasion beyond the hypoxic fraction in triple-negative breast cancer

nature.com

We were delighted to celebrate Sir Walter Bodmer's 90th birthday at a symposium held at Hertford College. Talks from some of Sir Bodmer's former students, colleagues, and collaborators reflected on his extraordinary career spanning seven decades.

Researchers have developed a novel OXPHOS inhibitor designed to reduce tumour hypoxia, a major cause of radiotherapy resistance. By reducing oxygen consumption in tumour cells, the compound increases oxygen availability within tumours, alleviating hypoxia & potentially increasing radiosensitivity.

New compound developed to target hypoxia by reducing tumour oxygen consumption

Researchers have developed a promising new compound designed to reduce tumour hypoxia, a major cause of radiotherapy resistance.

oncology.ox.ac.uk

It was a pleasure to host Dr Jemma Longley from @unisouthampton.bsky.social for our GO-PRECISE Seminar Series focused on early cancer detection & prevention. Dr Longley shared exciting insights from the VIOLET Study, which is looking at vaginal fluid biomarkers for early detection of ovarian cancer

📢 Join us: Research Assistant in Cancer Immunogenetics We have an exciting opportunity to join Prof. Ben Fairfax’s research group, focused on understanding how host immunity and genetic variation influence responses to cancer immunotherapy. See more details: www.oncology.ox.ac.uk/about-us/cur...

NEWS: Oxford researchers join €50m European study on heart health in cancer patients  Read more about this joint research project. @oncology.ox.ac.uk  

Oxford researchers join €50m European study on heart health in cancer patients

Researchers from the Department of Oncology are part of a €50 million European project looking at how innovative medical and digital technologies can improve the early detection of heart-related problems in cancer patients and survivors.

medsci.ox.ac.uk

NEWS: Study reveals lifetime obesity exposure in cancer patients is widely underestimated Read about this new study from @oncology.ox.ac.uk 

Study reveals lifetime obesity exposure in cancer patients is widely underestimated

New data published today in the European Society for Medical Oncology (ESMO) Real World Data and Digital Oncology show that more than half of people receiving systemic anticancer treatment had a history of obesity, compared with only around one in four who were classified as obese at the time their treatment began.

medsci.ox.ac.uk

There's still a few spaces left to attend our second annual Oxford Liver Cancer Centre of Excellence Symposium! Register before EOD today to secure your place! Details below 👇 @oncology.ox.ac.uk @medsci.ox.ac.uk @mplsoxford.bsky.social

Oxford Cancer@oxfordcancer.bsky.social · 4mo ago

Our second annual Oxford Liver Cancer Centre of Excellence Symposium will focus on advancing scientific collaboration and ultimately improving outcomes for liver cancer! 🥼When: 14th May 🧪Where: Richard Doll Building @medsci.ox.ac.uk @oncology.ox.ac.uk www.eventbrite.co.uk/e/oxford-liv...

EVENT: Health research showcase Organised by @oxfordbrc.bsky.social and @oxhealthbrc.bsky.social, this is an opportunity to enjoy hands-on activities while learning about research taking place in Oxford. Thur 28 May https://oxfordbrc.nihr.ac.uk/brc-event/health-research-showcase-event-2025/

NEWS: New funding to fast-track ultra-fast FLASH radiotherapy into the clinic The EPSRC-funded project aims to advance the technique that may reduce treatment side effects. @oncology.ox.ac.uk 

New funding to fast-track ultra-fast FLASH radiotherapy into the clinic

A new EPSRC-funded research project led by Dr Kristoffer Petersson aims to advance the clinical implementation of FLASH radiotherapy, an emerging technique that delivers radiation in a fraction of a second and may significantly reduce treatment side effects.

medsci.ox.ac.uk

Prof Dan McGowan will play a key role in an EU-funded project looking at how medical and digital tech – in his case, routine PET scans - can help us detect heart problems in cancer patients quicker. 📰 www.ouh.nhs.uk/news/articles/2386 @oncology.ox.ac.uk @ihieurope.bsky.social

Our second annual Oxford Liver Cancer Centre of Excellence Symposium will focus on advancing scientific collaboration and ultimately improving outcomes for liver cancer! 🥼When: 14th May 🧪Where: Richard Doll Building @medsci.ox.ac.uk @oncology.ox.ac.uk www.eventbrite.co.uk/e/oxford-liv...

Oxford Liver Cancer Centre of Excellence 2026 Symposium

An event focused on advancing scientific collaboration and improving outcomes for liver cancer.

eventbrite.co.uk

How can we make radiotherapy faster, safer, and more accessible? Dr Kristoffer Petersson has secured £1.87M in EPSRC funding to develop megavoltage photon FLASH radiotherapy technology, an ultra-fast approach that could reduce harm to healthy tissue while maintaining effectiveness.

New funding to fast-track ultra-fast FLASH radiotherapy into the clinic

A new EPSRC-funded research project led by Dr Kristoffer Petersson aims to advance the clinical implementation of FLASH radiotherapy, an emerging technique that delivers radiation in a fraction of a s...

oncology.ox.ac.uk

MILI participant Abbi talks about Li Fraumeni Syndrome and her experience of joining the MILI trial: mili.octru.ox.ac.uk/hear-from-a-... To learn about the MILI trial and LFS, visit mili.octru.ox.ac.uk #TP53 #LiFraumeniSyndrome #LFS @oncology.ox.ac.uk @oxfordcancer.bsky.social

Calling all early career researchers with an @ouhospitals.bsky.social contract!   The OHSRC are offering grants of up to £10K to NHS staff (including honorary contracts) whose research will help patients of the OUH. Deadline: Wed 15 April   Apply ➡️ https://www.ouh.nhs.uk/researchers/grants/

🆕New research from the Petersson lab, published in the British Journal of Radiology The team studied FLASH vs conventional radiotherapy in muscle invasive bladder cancer models, demonstrating enhanced survival through effective dose escalation using FLASH.

FLASH radiotherapy enables dose escalation and improves survival in an orthotopic muscle-invasive bladder cancer mouse model

AbstractObjectives. FLASH radiotherapy is an innovative technique that delivers radiation at ultra-high dose rates (UHDR), offering tumour control comparab

academic.oup.com

Kicking off our 'New to Oxford' talks at #OxSymp26 today, Lucy Brooks @oncology.ox.ac.uk discusses how neurodevelopmental and injury programs shape glioblastoma and therapy response.

MILI participant Abbi talks about Li Fraumeni Syndrome and joining the MILI trial: www.instagram.com/p/DWULPq8gSM... To learn about the MILI trial and LFS, visit mili.octru.ox.ac.uk #TP53 #LiFraumeniSyndrome #LFS @oncology.ox.ac.uk @oxfordcancer.bsky.social

Published today in @natmed.nature.com, researchers from @ox.ac.uk & MUHAS, Tanzania have shown that a minimally invasive liquid biopsy test can diagnose Burkitt lymphoma rapidly and accurately in sub-Saharan Africa, where delays in traditional testing often prove fatal. @oxfordcancer.bsky.social

Blood Test May Improve Survival of Childhood Cancer in Africa

In a study published today in Nature Medicine, researchers from the University of Oxford and the Muhimbili University of Health and Allied Sciences (MUHAS) in Dar es salaam, Tanzania have shown that a...

oncology.ox.ac.uk

Why are some oesophageal cancers so difficult to treat? @oncology.ox.ac.uk researchers found the most aggressive tumours have high chromosomal instability - meaning cancer cells constantly make mistakes as they divide, helping them adapt and resist treatment. More info ⬇️

New research reveals why some oesophageal cancers are so hard to

Research published in Science Advances has uncovered new insights into why the most aggressive oesophageal cancers are so difficult to treat and how the body’s own defence systems are helping them to

ox.ac.uk

New research led by @eileenparkes.bsky.social and co-authored by DPhil in Cancer Science Alumnus, Bruno Beernaert @oncology.ox.ac.uk, has uncovered new insights into why the most aggressive oesophageal cancers are so difficult to treat. 👇 www.cancer.ox.ac.uk/news/new-res...

New Research Reveals Why Some Oesophageal Cancers are So Hard to Treat

Research published today in Science Advances has uncovered new insights into why the most aggressive oesophageal cancers are so difficult to treat and how the body’s own defence systems are helping th...

cancer.ox.ac.uk

Celebrating some of the brilliant women in our team and the trailblazers who inspire them this International Day of Women and Girls in Science 👩‍🔬✨ Scroll through below ⬇️⬇️ #WomenInScience #InternationalDayOfWomenAndGirlsInScience

Aglaia Skolariki, 2nd year Clinical Research Training Fellow, is researching how abnormal cell division in aggressive cancers drives particular genetic changes. 👇#InternationalDayofWomenAndGirlsInScience2026 @medsci.ox.ac.uk @oncology.ox.ac.uk @oxcio.bsky.social www.cancer.ox.ac.uk/news/interna...